These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 22614575

  • 21. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.
    Atkinson BJ, Cauley DH, Ng C, Millikan RE, Xiao L, Corn P, Jonasch E, Tannir NM.
    BJU Int; 2014 Mar; 113(3):376-82. PubMed ID: 24053120
    [Abstract] [Full Text] [Related]

  • 22. [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].
    Shuuin T, Karashima H.
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1076-9. PubMed ID: 19620795
    [Abstract] [Full Text] [Related]

  • 23. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.
    Boni JP, Hug B, Leister C, Sonnichsen D.
    Semin Oncol; 2009 Dec; 36 Suppl 3():S18-25. PubMed ID: 19963096
    [Abstract] [Full Text] [Related]

  • 24. mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review.
    Gerullis H, Ecke TH, Eimer C, Heuck CJ, Otto T.
    Minerva Urol Nefrol; 2010 Dec; 62(4):411-23. PubMed ID: 20944541
    [Abstract] [Full Text] [Related]

  • 25. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA.
    Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
    [Abstract] [Full Text] [Related]

  • 26. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
    Hudes GR, Berkenblit A, Feingold J, Atkins MB, Rini BI, Dutcher J.
    Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
    [Abstract] [Full Text] [Related]

  • 27. [Metastatic renal cell carcinoma treated with everolimus--data from the RENIS Clinical Registry].
    Büchler T, Dusek L, Fínek J, Poprach A, Budnáková D, Kandrnal V, Jarkovský J, Bortlícek Z, Klimes D, Abrahámová J, Vyzula R.
    Klin Onkol; 2011 Dec; 24(5):389-92. PubMed ID: 22070021
    [Abstract] [Full Text] [Related]

  • 28. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY, Grossman AB, Bukowski RM.
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [Abstract] [Full Text] [Related]

  • 29. Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.
    Nozawa M, Ohzeki T, Tamada S, Hongo F, Anai S, Fujimoto K, Miki T, Nakatani T, Fukasawa S, Uemura H.
    Int J Clin Oncol; 2015 Aug; 20(4):790-5. PubMed ID: 25342378
    [Abstract] [Full Text] [Related]

  • 30. Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma.
    Ekshyyan O, Mills GM, Lian T, Amirghahari N, Rong X, Lowery-Nordberg M, Abreo F, Veillon DM, Caldito G, Speicher L, Glass J, Nathan CO.
    Head Neck; 2010 Dec; 32(12):1619-28. PubMed ID: 20222045
    [Abstract] [Full Text] [Related]

  • 31. Management of mTOR inhibitor side effects.
    Creel PA.
    Clin J Oncol Nurs; 2009 Dec; 13 Suppl():19-23. PubMed ID: 19948456
    [Abstract] [Full Text] [Related]

  • 32. [Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].
    Mounier N, Vignot S, Spano JP.
    Bull Cancer; 2006 Nov; 93(11):1139-43. PubMed ID: 17145584
    [Abstract] [Full Text] [Related]

  • 33. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.
    Maroto JP, Hudes G, Dutcher JP, Logan TF, White CS, Krygowski M, Cincotta M, Shapiro M, Duran I, Berkenblit A.
    J Clin Oncol; 2011 May 01; 29(13):1750-6. PubMed ID: 21444868
    [Abstract] [Full Text] [Related]

  • 34. [Adverse events associated with temsirolimus for patients with metastatic renal cell carcinoma].
    Miyake H, Fujisawa M.
    Hinyokika Kiyo; 2012 Nov 01; 58(11):651-4. PubMed ID: 23254795
    [Abstract] [Full Text] [Related]

  • 35. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O, Smolewski P.
    Future Med Chem; 2012 Mar 01; 4(4):487-504. PubMed ID: 22416776
    [Abstract] [Full Text] [Related]

  • 36. A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma.
    Plimack ER, Tan T, Wong YN, von Mehren MM, Malizzia L, Roethke SK, Litwin S, Li T, Hudes GR, Haas NB.
    Oncologist; 2014 Apr 01; 19(4):354-5. PubMed ID: 24674872
    [Abstract] [Full Text] [Related]

  • 37. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
    Shameem R, Lacouture M, Wu S.
    Cancer Invest; 2015 Mar 01; 33(3):70-7. PubMed ID: 25635371
    [Abstract] [Full Text] [Related]

  • 38. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
    Kapoor A, Figlin RA.
    Cancer; 2009 Aug 15; 115(16):3618-30. PubMed ID: 19479976
    [Abstract] [Full Text] [Related]

  • 39. Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma.
    Lamm W, Vogl UM, Bojic M, Zielinski C, Klingler C, Kramer G, Schmidinger M.
    Acta Oncol; 2012 Jan 15; 51(1):101-6. PubMed ID: 21736504
    [Abstract] [Full Text] [Related]

  • 40. mTOR inhibitors in advanced renal cell carcinoma.
    Voss MH, Molina AM, Motzer RJ.
    Hematol Oncol Clin North Am; 2011 Aug 15; 25(4):835-52. PubMed ID: 21763970
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.